搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
The Lancet
9 小时
Rating the response of primary aldosteronism to targeted medical treatment with the PAMO ...
The consequences of primary aldosteronism mainly result from the activation of the mineralocorticoid receptor. Two of these ...
The Lancet
1 天
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention
Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...
Monthly Prescribing Reference
1 天
Community-Acquired AKI Linked to NSAIDs
Use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially over-the-counter formulations, and certain other drug classes are among the risk factors for community-acquired acute kidney injury (CA ...
2 天
on MSN
You may have rare disorder rather than the flu, says NHS
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
2 天
The rare disorder the NHS says could be mistaken for the flu
The NHS is cautioning that during this time of year, it might be easy to confuse flu symptoms with those of a rare condition.
independentaustralia.net
3 天
Research Peptides in Cardiac Research and Science: A Molecular Perspective
Peptides have emerged as a focal point in molecular and biological research, providing a promising avenue for understanding ...
Knowridge
4 天
New CT scan can detect hidden cause of high blood pressure
A groundbreaking type of CT scan has been developed that can identify tiny nodules in a hormone gland, offering a potential ...
Pharmabiz
4 天
Mineralys Therapeutics gets US FDA nod to begin phase 2 trial of lorundrostat for OSA in ...
Radnor, Pennsylvania Friday, January 10, 2025, 18:00 Hrs [IST] ...
5 天
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials
An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...
6 天
Strategic Advancements and FDA Clearance Propel Mineralys Therapeutics to a Buy Rating
Mineralys Therapeutics, Inc. (MLYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
marketinference
6 天
FDA Clears Mineralys Therapeutics' IND for OSA and Hypertension Trial
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the clearance of its investigational new drug (IND) application by ...
6 天
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive ...
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈